Tonix Pharmaceuticals Scores Key U.S. Patent For New Migraine Treatment Delivery Method
Tonix Pharmaceuticals secures U.S. patent for Tosymra® intranasal migraine treatment, effective until 2030.
Breaking News
Sep 20, 2024
Mrudula Kulkarni
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical
company with a range of products and a robust pipeline, has announced that it
has been granted U.S. Patent No. 12,090,139 by the United States Patent and
Trademark Office on September 17, 2024. This patent covers "Formulations
Comprising Triptan Compounds" and includes claims related to a
pharmaceutical composition, a method for treating migraines through intranasal
delivery, and an intranasal system specifically for Tosymra®. The patent is set
to remain in effect until 2030, barring any potential extensions.
Seth Lederman, M.D., Chief Executive Officer of Tonix
Pharmaceuticals, said “We believe this patent further solidifies Tosymra® in
the market as a differentiated drug with a differentiated administration
method. This new patent targets specific delivery and composition. We are
thrilled to have these additional issued patent claims, which add to the
intellectual property protection existing for Tosymra®.”
In the U.S., close to 40 million individuals are affected by
migraines, which is also identified as the second most common cause of
disability globally. Migraines are marked by intense and debilitating episodes
lasting from four to 72 hours. These attacks often involve throbbing headaches
of moderate to severe pain, accompanied by symptoms such as nausea, vomiting,
and heightened sensitivity to both light (photophobia) and sound (phonophobia).